NCT01535885View on ClinicalTrials.gov

Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Epstein-Barr Virus InfectionsAdenovirusCytomegalovirus Infections
Interventions
BIOLOGICAL

Cytotoxic T Lymphocytes

Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.

Trial Locations (1)

53226

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT01535885 - Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV | Biotech Hunter | Biotech Hunter